Ashley N Reeb1, Wen Li, Will Sewell, Laura A Marlow, Han W Tun, Robert C Smallridge, John A Copland, Kyle Spradling, Rebecca Chernock, Reigh-Yi Lin. 1. Department of Otolaryngology (A.N.R., W.L., W.S., K.S., R-Y.L.), Head and Neck Surgery, St. Louis University School of Medicine, St Louis, Missouri 63104; Department of Cancer Biology (L.A.M., J.A.C.), Division of Hematology/Oncology (H.W.T.), and Division of Endocrinology (R.C.S.), Mayo Clinic, Jacksonville, Florida 32224; Department of Pathology and Immunology (R.C.), Washington University School of Medicine, St Louis, Missouri 63110.
Abstract
CONTEXT: Anaplastic thyroid carcinoma (ATC) is one of the most deadly human malignancies. It is 99% lethal, and patients have a median survival of only 6 months after diagnosis. Despite these grim statistics, the mechanism underlying the tumorigenic capability of ATC cells is unclear. OBJECTIVE: S100A8 and S100A9 proteins have emerged as critical mediators in cancer. The aim was to investigate the expression and function of S100A8 and S100A9 in ATC and the mechanisms involved. DESIGN: We determined the expression of S100A8 and S100A9 in human ATC by gene array analysis and immunohistochemistry. Using RNAi-mediated stable gene knockdown in human ATC cell lines and bioluminescent imaging of orthotopic and lung metastasis mouse models of human ATC, we investigated the effects of S100A8 and S100A9 on tumorigenesis and metastasis. RESULTS: We demonstrated that S100A8 and S100A9 were overexpressed in ATC but not in other types of thyroid carcinomas. In vivo analysis in mice using ATC cells that had S100A8 knocked down revealed reduced tumor growth and lung metastasis, as well as significantly prolonged animal survival. Mechanistic investigations showed that S100A8 promotes ATC cell proliferation through an interaction with RAGE, which activates the p38, ERK1/2 and JNK signaling pathways in the tumor cells. CONCLUSIONS: These findings establish a novel role for S100A8 in the promoting and enhancing of ATC progression. They further suggest that the inhibition of S100A8 could represent a relevant therapeutic target, with the potential of enabling a more effective treatment path for this deadly disease.
CONTEXT: Anaplastic thyroid carcinoma (ATC) is one of the most deadly humanmalignancies. It is 99% lethal, and patients have a median survival of only 6 months after diagnosis. Despite these grim statistics, the mechanism underlying the tumorigenic capability of ATC cells is unclear. OBJECTIVE:S100A8 and S100A9 proteins have emerged as critical mediators in cancer. The aim was to investigate the expression and function of S100A8 and S100A9 in ATC and the mechanisms involved. DESIGN: We determined the expression of S100A8 and S100A9 in human ATC by gene array analysis and immunohistochemistry. Using RNAi-mediated stable gene knockdown in human ATC cell lines and bioluminescent imaging of orthotopic and lung metastasis mouse models of human ATC, we investigated the effects of S100A8 and S100A9 on tumorigenesis and metastasis. RESULTS: We demonstrated that S100A8 and S100A9 were overexpressed in ATC but not in other types of thyroid carcinomas. In vivo analysis in mice using ATC cells that had S100A8 knocked down revealed reduced tumor growth and lung metastasis, as well as significantly prolonged animal survival. Mechanistic investigations showed that S100A8 promotes ATC cell proliferation through an interaction with RAGE, which activates the p38, ERK1/2 and JNK signaling pathways in the tumor cells. CONCLUSIONS: These findings establish a novel role for S100A8 in the promoting and enhancing of ATC progression. They further suggest that the inhibition of S100A8 could represent a relevant therapeutic target, with the potential of enabling a more effective treatment path for this deadly disease.
Authors: Swarnali Acharyya; Thordur Oskarsson; Sakari Vanharanta; Srinivas Malladi; Juliet Kim; Patrick G Morris; Katia Manova-Todorova; Margaret Leversha; Nancy Hogg; Venkatraman E Seshan; Larry Norton; Edi Brogi; Joan Massagué Journal: Cell Date: 2012-07-06 Impact factor: 41.582
Authors: Laura A Marlow; Jaclyn D'Innocenzi; Yilin Zhang; Stephen D Rohl; Simon J Cooper; Thomas Sebo; Clive Grant; Bryan McIver; Jan L Kasperbauer; J Trad Wadsworth; John D Casler; Pamela W Kennedy; W Edward Highsmith; Orlo Clark; Dragana Milosevic; Brian Netzel; Kendall Cradic; Shilpi Arora; Christian Beaudry; Stefan K Grebe; Marc L Silverberg; David O Azorsa; Robert C Smallridge; John A Copland Journal: J Clin Endocrinol Metab Date: 2010-09-01 Impact factor: 5.958
Authors: Saeid Ghavami; Iran Rashedi; Brian M Dattilo; Mehdi Eshraghi; Walter J Chazin; Mohammad Hashemi; Sebastian Wesselborg; Claus Kerkhoff; Marek Los Journal: J Leukoc Biol Date: 2008-03-13 Impact factor: 4.962
Authors: Robert C Smallridge; Kenneth B Ain; Sylvia L Asa; Keith C Bible; James D Brierley; Kenneth D Burman; Electron Kebebew; Nancy Y Lee; Yuri E Nikiforov; M Sara Rosenthal; Manisha H Shah; Ashok R Shaha; R Michael Tuttle Journal: Thyroid Date: 2012-11 Impact factor: 6.568
Authors: Jennifer A Morrison; Laura A Pike; Greg Lund; Qiong Zhou; Brittelle E Kessler; Kevin T Bauerle; Sharon B Sams; Bryan R Haugen; Rebecca E Schweppe Journal: Horm Cancer Date: 2015-03-24 Impact factor: 3.869
Authors: P Jiménez-Fonseca; J M Gómez Saez; J Santamaria Sandi; J Capdevila; E Navarro Gonzalez; C Zafon Llopis; T Ramón Y Cajal Asensio; G Riesco-Eizaguirre; E Grande; J C Galofré Journal: Clin Transl Oncol Date: 2016-04-05 Impact factor: 3.405
Authors: Caitlin E Egan; Dessislava Stefanova; Adnan Ahmed; Vijay J Raja; Jessica W Thiesmeyer; Kevin J Chen; Jacques A Greenberg; Taotao Zhang; Bing He; Brendan M Finnerty; Rasa Zarnegar; Moonsoo M Jin; Theresa Scognamiglio; Noah Dephoure; Thomas Fahey; Irene M Min Journal: Thyroid Date: 2021-07-05 Impact factor: 6.506